Resignation of Ms. Dolly Mandhan, Company Secretary and Compliance Officer w.e.f. 14.08.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical's board met on 14 August 2025 and approved several items in one go. Unaudited results for Q1 FY26 (quarter ended 30 June 2025) show total income of Rs 1,513.47 lakhs, up from Rs 1,262.08 lakhs in the same quarter last year. However, the loss before tax ballooned to Rs 814.80 lakhs from Rs 281.70 lakhs, and the net loss widened to Rs 610.61 lakhs from Rs 136.33 lakhs a year ago. The board appointed new Internal, Secretarial, and Cost Auditors for FY 2025-26. Ms. Dolly Mandhan resigned as Company Secretary and Compliance Officer citing personal reasons, and Ms. Kumkum Bajaj was appointed as her replacement effective the same day.
Widening quarterly losses despite higher revenue suggest rising costs or pricing pressure, which is negative for shareholders. The Company Secretary change appears routine with an immediate replacement, so it should not materially affect compliance or operations.